vs
Side-by-side financial comparison of BOYD GAMING CORP (BYD) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $997.4M, roughly 1.1× BOYD GAMING CORP). Hologic runs the higher net margin — 17.1% vs 10.5%, a 6.6% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs 0.6%). Over the past eight quarters, BOYD GAMING CORP's revenue compounded faster (1.5% CAGR vs 1.5%).
Boyd Gaming Corporation is an American gambling and hospitality company based in Paradise, Nevada, US.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
BYD vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $997.4M | $1.0B |
| Net Profit | $104.3M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 16.4% | 22.6% |
| Net Margin | 10.5% | 17.1% |
| Revenue YoY | 0.6% | 2.5% |
| Net Profit YoY | -5.9% | -10.9% |
| EPS (diluted) | $1.37 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $997.4M | — | ||
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | $1.0B | ||
| Q1 25 | $991.6M | $1.0B | ||
| Q4 24 | $1.0B | $1.0B | ||
| Q3 24 | $961.2M | $988.0M | ||
| Q2 24 | $967.5M | $1.0B |
| Q1 26 | $104.3M | — | ||
| Q4 25 | $140.4M | $179.1M | ||
| Q3 25 | $1.4B | $187.2M | ||
| Q2 25 | $151.5M | $194.9M | ||
| Q1 25 | $111.4M | $-17.4M | ||
| Q4 24 | $170.5M | $201.0M | ||
| Q3 24 | $131.1M | $178.6M | ||
| Q2 24 | $139.8M | $194.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% |
| Q1 26 | 16.4% | — | ||
| Q4 25 | 15.7% | 22.6% | ||
| Q3 25 | 13.9% | 22.6% | ||
| Q2 25 | 23.4% | 24.9% | ||
| Q1 25 | 20.2% | -0.7% | ||
| Q4 24 | 25.1% | 22.5% | ||
| Q3 24 | 22.9% | 23.3% | ||
| Q2 24 | 23.5% | 24.1% |
| Q1 26 | 10.5% | — | ||
| Q4 25 | 13.2% | 17.1% | ||
| Q3 25 | 143.4% | 17.8% | ||
| Q2 25 | 14.6% | 19.0% | ||
| Q1 25 | 11.2% | -1.7% | ||
| Q4 24 | 16.4% | 19.7% | ||
| Q3 24 | 13.6% | 18.1% | ||
| Q2 24 | 14.5% | 19.2% |
| Q1 26 | $1.37 | — | ||
| Q4 25 | $1.60 | $0.79 | ||
| Q3 25 | $17.81 | $0.84 | ||
| Q2 25 | $1.84 | $0.86 | ||
| Q1 25 | $1.31 | $-0.08 | ||
| Q4 24 | $1.89 | $0.87 | ||
| Q3 24 | $1.43 | $0.75 | ||
| Q2 24 | $1.47 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | — | $5.2B |
| Total Assets | — | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $353.4M | $2.4B | ||
| Q3 25 | $319.1M | $2.2B | ||
| Q2 25 | $320.1M | $1.9B | ||
| Q1 25 | $311.5M | $1.6B | ||
| Q4 24 | $316.7M | $2.0B | ||
| Q3 24 | $286.3M | $2.3B | ||
| Q2 24 | $280.8M | $2.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | $3.6B | $2.5B | ||
| Q1 25 | $3.5B | $2.5B | ||
| Q4 24 | $3.2B | $2.5B | ||
| Q3 24 | $3.1B | $2.5B | ||
| Q2 24 | $3.0B | $2.5B |
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | $5.2B | ||
| Q3 25 | $2.7B | $5.0B | ||
| Q2 25 | $1.4B | $4.8B | ||
| Q1 25 | $1.3B | $4.6B | ||
| Q4 24 | $1.6B | $4.8B | ||
| Q3 24 | $1.6B | $5.1B | ||
| Q2 24 | $1.7B | $5.0B |
| Q1 26 | — | — | ||
| Q4 25 | $6.6B | $9.2B | ||
| Q3 25 | $6.5B | $9.0B | ||
| Q2 25 | $6.6B | $8.8B | ||
| Q1 25 | $6.5B | $8.5B | ||
| Q4 24 | $6.4B | $8.7B | ||
| Q3 24 | $6.3B | $9.2B | ||
| Q2 24 | $6.3B | $8.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | 2.56× | 0.52× | ||
| Q1 25 | 2.61× | 0.55× | ||
| Q4 24 | 2.01× | 0.53× | ||
| Q3 24 | 1.88× | 0.49× | ||
| Q2 24 | 1.73× | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $275.3M | $229.9M | ||
| Q3 25 | $240.0M | $355.1M | ||
| Q2 25 | $205.0M | $343.3M | ||
| Q1 25 | $256.4M | $169.4M | ||
| Q4 24 | $262.1M | $189.3M | ||
| Q3 24 | $231.2M | $367.0M | ||
| Q2 24 | $213.1M | $405.8M |
| Q1 26 | — | — | ||
| Q4 25 | $127.0M | $215.2M | ||
| Q3 25 | $94.4M | $341.4M | ||
| Q2 25 | $80.6M | $330.5M | ||
| Q1 25 | $86.5M | $153.9M | ||
| Q4 24 | $150.9M | $172.5M | ||
| Q3 24 | $146.0M | $350.6M | ||
| Q2 24 | $98.7M | $385.3M |
| Q1 26 | — | — | ||
| Q4 25 | 12.0% | 20.5% | ||
| Q3 25 | 9.4% | 32.5% | ||
| Q2 25 | 7.8% | 32.3% | ||
| Q1 25 | 8.7% | 15.3% | ||
| Q4 24 | 14.5% | 16.9% | ||
| Q3 24 | 15.2% | 35.5% | ||
| Q2 24 | 10.2% | 38.1% |
| Q1 26 | — | — | ||
| Q4 25 | 14.0% | 1.4% | ||
| Q3 25 | 14.5% | 1.3% | ||
| Q2 25 | 12.0% | 1.3% | ||
| Q1 25 | 17.1% | 1.5% | ||
| Q4 24 | 10.7% | 1.6% | ||
| Q3 24 | 8.9% | 1.7% | ||
| Q2 24 | 11.8% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.96× | 1.28× | ||
| Q3 25 | 0.17× | 1.90× | ||
| Q2 25 | 1.35× | 1.76× | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 1.54× | 0.94× | ||
| Q3 24 | 1.76× | 2.05× | ||
| Q2 24 | 1.52× | 2.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BYD
| Gaming | $650.5M | 65% |
| Online reimbursements | $135.4M | 14% |
| Food & beverage | $75.8M | 8% |
| Other | $63.5M | 6% |
| Room | $45.9M | 5% |
| Management fee | $26.2M | 3% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
